Physicians and nurses seeking credit for this activity, please visit https://education.gotoper.com//activity/ectrims21ms-enduring
Program Description
The COVID-19 pandemic is an unprecedented health care crisis with disproportionate impact on immunocompromised populations. There are unanswered questions and a lack of understanding about the immune response to SARS-CoV-2 vaccines in patients with multiple sclerosis (MS) treated with disease modifying therapies (DMTs). With a continually changing therapeutic landscape based on emerging evidence, clinicians managing patients with MS require timely education on balancing SARS-CoV-2 infection risk with optimal disease control. This program sheds more light on cell-mediated responses to vaccines, how SARS-CoV-2 vaccines work, and current evidence surrounding DMTs for MS and vaccine response.
Target Audience: Specialty pharmacists
Type of Activity: Application
Release date: December 23, 2021
Expiration date: December 23, 2022
Time to complete activity: 1.25 hours
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Describe the immunological pathways activated by vaccine administration
- Explain the mechanisms underlying the antiviral efficacy of current SARSCoV-2 vaccines
- Discuss the impact of disease-modifying therapies (DMTs) on anti-SARS-CoV-2 vaccine response in patients with MS
- Implement timely, evidence-based strategies for addressing COVID-19 in patients with MS
Matthew A. Tremblay, MD, PhD
Director of Multiple Sclerosis Research
Multiple Sclerosis Comprehensive Care Canter
Department of Medicine
RWJ Barnabas Health
Livingston, New Jersey
Aimee M. Banks, PharmD, BCPS, MSCS
Clinical Pharmacist, Multiple Sclerosis
Vanderbilt University Medical Center
Nashville, Tennessee
Joseph J. Sabatino, Jr., MD, PhD
Assistant Adjunct Professor
Department of Neurology
University of California San Francisco
San Francisco, CA
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.25 contact hours (0.125 CEU) under the ACPE universal activity number 0290-0000-21-431-H01-P. The activity is available for CE credit through December 23, 2022.
Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, view the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
Disclosures
Faculty
Matthew A. Tremblay, MD, PhD, has the following relevant financial relationships with commercial interests to disclose:
Grant/Research Support: Biogen
Consultant: Genentech
Speaker’s Bureau: Genentech
Aimee M. Banks, PharmD, BCPS, MSCS, has the following relevant financial relationships with commercial interests to disclose:
Advisory Board Consultant: Bristol Myers Squibb, EMD Serono, TG Therapeutics
Joseph J. Sabatino, Jr., MD, PhD, has the following relevant financial relationships with commercial interests to disclose:
Grant/Research Support: Novartis Pharmaceuticals
Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Crissy Wilson; Susan Pordon; Brianna Winters; and Chloe Taccetta
An anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.
Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.
For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here